Biothrax
Total Payments
$4.8M
Transactions
5,153
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2.6M | 161 | 0 |
| 2020 | $2.2M | 4,992 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.8M | 5,153 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EBS.AVA.212 | Emergent BioSolutions Inc. | $2.2M | 0 |
| VELOCITY: An Anthrax Vaccine Clinical Study | Emergent BioSolutions Inc. | $1.7M | 2 |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study | Emergent BioSolutions Inc. | $470,897 | 0 |
| EBS.AVA.210 | Emergent BioSolutions Inc. | $408,264 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.8M
- Total Doctors 2
- Transactions 5,153
About Biothrax
Biothrax is a drug associated with $4.8M in payments to 2 healthcare providers, recorded across 5,153 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2020 to 2021. In 2021, $2.6M was paid across 161 transactions to 0 doctors.
The most common payment nature for Biothrax is "Unspecified" ($4.8M, 100.0% of total).
Biothrax is associated with 4 research studies, including "EBS.AVA.212" ($2.2M).